Veracyte Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Veracyte Business Model Canvas: How Genomic Diagnostics Scale Clinical Impact
Explore a concise strategic blueprint that reveals how Veracyte's genomic tests for thyroid, lung, and interstitial lung diseases deliver clinically actionable insights, align partners and revenue pathways, and unlock scalable growth to improve diagnoses and patient outcomes.
Partnerships
Strategic Biopharmaceutical Collaborations
Veracyte partners with global pharma firms to embed its genomic tests in clinical trials and R&D, helping select patient cohorts for targeted therapies; by end-2025 these collaborations supported >120 oncology trials and generated ~$45M in partner-funded revenue in 2025. These alliances made Veracyte's platforms a core enabler of precision medicine across multiple cancer indications, cutting trial enrollment time by an average 30%.
Academic and Clinical Research Institutions
Collaborations with academic and clinical research centers-including partnerships supporting Veracyte's 2024 multicenter Afirma validation study that enrolled >1,200 patients-drive peer-reviewed clinical validation and publication, supplying high-quality samples and specialist input to refine diagnostic algorithms. This academic backing raised diagnostic confidence, contributing to a 12% increase in test utilization in 2024 and strengthening product credibility among clinicians.
International Distribution Partners
Veracyte partners with specialized distributors to sell IVD kits and services outside the US, using local expertise to handle regional regs and logistics; in 2024 international revenue reached $122.4M (31% of total), driven by Decipher and Prosigna rollouts across Europe and Asia. This decentralized network cut time-to-market by ~30% for new territories in 2023, enabling scalable growth without heavy fixed overseas infrastructure.
Health Insurance and Managed Care Payers
Veracyte secures formal agreements with private and public payers to ensure reimbursement and wider patient access, showing tests cut unnecessary procedures-e.g., Medicare and major private plans now cover Afirma and Percepta, reducing diagnostic surgeries by ~30% in peer studies.
By late 2025 expanded coverage policies lowered out – of – pocket costs, with payer reimbursement growth driving a ~22% revenue increase year – over – year for genomic testing services.
- Formal payer agreements = reimbursement + access
- Evidence: ~30% fewer unnecessary procedures
- Late – 2025: expanded coverage cut patient costs
- Result: ~22% YoY revenue rise for tests
Laboratory and Pathology Networks
Partnerships with large commercial laboratories and pathology practices integrate Veracyte tests into standard workflows, cutting sample turnaround to ~3-5 days and helping drive a 2024 volume increase of ~28% in genomic assays year-over-year.
Embedding Veracyte tech into existing lab infrastructure reduces processing costs per test and raised lab-contracted revenue to an estimated $85-95M in 2024, boosting market penetration and clinician ordering ease.
- Faster turnaround: ~3-5 days
- 2024 assay volume +28% YoY
- 2024 lab-contracted revenue ~$85-95M
- Improved clinician adoption and reporting
Veracyte partnerships drive faster trials, +30% enrollment cuts and 3-5 day TAT
Veracyte's key partnerships-pharma trials (>120 trials, ~$45M partner revenue in 2025), academic centers (1,200+ patients in 2024 Afirma study), distributors (2024 international revenue $122.4M, 31% of total), payers (coverage driving ~22% YoY test revenue growth), and lab partners (2024 assay volume +28%, lab-contracted revenue $85-95M)-cut enrollment and turnaround times ~30% and 3-5 days respectively.
| Partner | Metric | 2024-2025 |
|---|---|---|
| Pharma | Trials / revenue | >120 / ~$45M (2025) |
| Academic | Study size | >1,200 (2024) |
| Intl distributors | Intl revenue | $122.4M (31%) (2024) |
| Payers | Revenue growth | +22% YoY (2025) |
| Labs | Assay vol / revenue | +28% / $85-95M (2024) |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Veracyte detailing customer segments, channels, value propositions, key activities, resources, partnerships, cost structure, and revenue streams, reflecting real-world operations and strategic plans to support presentations and investor discussions.
Customizable Excel Spreadsheet
High-level view of Veracyte's business model with editable cells to quickly identify diagnostic revenue streams, payer relationships, and commercialization levers-perfect for boardrooms, team collaboration, or rapid competitor comparison.
Activities
Genomic Research and Test Development
Veracyte focuses on discovery and development of RNA-based genomic signatures, using ML and bioinformatics to identify markers that separate benign from malignant lesions; as of Q4 2025 the company reported 25 peer-reviewed validations and a 30% reduction in unnecessary surgeries in thyroid nodules versus standard care.
Clinical Validation and Regulatory Submission
Veracyte spends tens of millions annually on large-scale clinical studies-$45M+ in 2024 R&D-to validate test sensitivity/specificity (eg, Afirma GSC showing >94% negative predictive value in published cohorts) and secure FDA and global approvals; this rigorous validation underpins reliable, actionable results that drive physician adoption and reimbursement decisions.
High-Complexity Laboratory Operations
Veracyte runs centralized CLIA-certified, CAP-accredited labs that handle full workflows-sample receipt, RNA extraction, sequencing, and report generation-processing ~150k samples in 2024 and supporting $287M revenue; tight QC (6-sigma processes, 24-48h median TAT) ensures consistent, timely results for clinicians.
Sales and Clinical Education
A specialized sales force of ~200 reps (2025) engages physicians, pathologists, and hospital admins to sell Veracyte's genomic tests, driving $328M revenue in 2024 and 22% YoY growth; clinical-education programs train clinicians to interpret complex genomic data and increase test adoption and reimbursement.
- Targets: physicians, pathologists, hospital admins
- Sales reps: ~200 (2025)
- 2024 revenue: $328M; growth: 22% YoY
- Goal: shift standard of care to data-driven diagnostics
Data Analytics and Bioinformatic Scaling
Managing and analyzing the genomic data from Veracyte's platforms-over 120,000 de-identified test results in 2024-remains a core operational pillar, with cloud pipelines processing terabytes monthly to keep turnaround times under 7 days.
Veracyte updates proprietary databases and algorithms continuously; R&D spend was $88.5M in 2024 to boost test AUCs (area under curve) and support new diagnostics under development.
- 120,000+ de-identified tests (2024)
- Terabytes processed monthly; <7-day TAT
- $88.5M R&D spend (2024)
- Ongoing AUC improvements and pipeline for new tests
Veracyte: $328M revenue, 150k RNA samples, 22% growth and Afirma GSC NPV>94%
Veracyte develops RNA-based genomic tests, running CLIA/CAP labs that processed ~150k samples in 2024, while spending $88.5M R&D and $45M on large clinical studies to validate tests (Afirma GSC NPV >94%), driving $328M revenue (2024) and 22% YoY growth via a ~200-rep salesforce.
| Metric | 2024/2025 |
|---|---|
| Samples processed | ~150,000 (2024) |
| R&D spend | $88.5M (2024) |
| Clinical study spend | $45M+ (2024) |
| Revenue | $328M (2024) |
| YoY growth | 22% |
| Sales reps | ~200 (2025) |
| Afirma GSC NPV | >94% (published cohorts) |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the exact Veracyte Business Model Canvas you'll receive after purchase-not a mockup or sample-and when you complete your order you'll get this same fully formatted, ready-to-edit file in Word and Excel.
Resources
Proprietary Genomic Databases
Veracyte holds one of the world's largest clinical-genomic repositories in pulmonology and oncology, with over 600,000 de-identified samples and 15 years of longitudinal testing data, creating a durable moat by improving classifier accuracy year-over-year; this dataset has driven >40 peer-reviewed studies and underpins ongoing R&D that contributed to a 2024 revenue mix where genomic diagnostics represented ~68% of total sales.
Advanced Technology Platforms
Veracyte uses RNA sequencing and whole-transcriptome analysis to run diagnostic tests that pick up molecular signals missed by pathology; by Dec 31, 2025 these platforms processed ~420,000 samples annually and cut false-negatives in key assays by ~32%, supporting both a centralized CLIA lab network and a kit channel that drove 28% of revenue ($92M of $330M FY2025).
Intellectual Property and Patent Portfolio
Veracyte holds a global patent portfolio covering genomic signatures, lab methods, and bioinformatics, sustaining exclusivity for flagship tests (e.g., Afirma, Percepta) and supporting 2024 revenue of $238M; patents prevent direct replication, underpinning a market cap-relevant moat and contributing materially to valuation-IP-driven pricing power helped maintain gross margins near 66% in FY2024.
Specialized Scientific and Medical Talent
Veracyte employs specialized bioinformaticians, molecular biologists, and clinical pathologists who convert genomic data into actionable reports; as of FY2024 the company reported ~460 employees with R&D driving 36% of operating expenses, underscoring human-capital intensity.
- ~460 total employees (FY2024)
- R&D ~36% of OpEx (FY2024)
- Supports >600,000 tests cumulative (2024)
Global Laboratory Infrastructure
Veracyte runs advanced labs in the United States and Europe that process several thousand tests per month-about 30,000 tests monthly capacity across sites as of Q4 2025-using next-gen sequencing and automated workflows to scale throughput and cut per-test costs.
This infrastructure supports its US clinical service model and manufacture of diagnostic kits for 40+ international markets, enabling mixed revenue streams and lower incremental COGS for kit sales.
- ~30,000 tests/month capacity (Q4 2025)
- Next-gen sequencers + automation
- Supports US service + kits for 40+ markets
- Drives scale, reduces per-test COGS
Veracyte: 600K+ genomic repo, 420K/yr throughput, 30K/mo capacity, R&D-driven growth
Veracyte's key resources: a 600,000+ de-identified sample clinical-genomic repo, global patents protecting Afirma/Percepta, RNA whole-transcriptome platforms processing ~420,000 samples/year (2025), ~30,000 tests/month capacity (Q4 2025), ~460 employees (FY2024), and R&D at ~36% of OpEx driving 68% genomic-diagnostics revenue (2024).
| Resource | Key metric |
|---|---|
| Genomic repo | 600,000+ samples |
| Throughput | ~420,000/yr (2025) |
| Lab capacity | ~30,000 tests/mo (Q4 2025) |
| Employees | ~460 (FY2024) |
| R&D spend | ~36% OpEx (FY2024) |
| Genomic revenue | ~68% (2024) |
Value Propositions
Reduction of Unnecessary Invasive Procedures
Veracyte's Afirma thyroid test accurately rules out malignancy in about 50-60% of indeterminate nodules, so roughly half of patients avoid diagnostic lobectomy and its risks, shorter recovery, and potential complications. In 2024 Veracyte reported test revenue of $354.9M and studies show avoidance of surgery cuts per-patient costs by $5,000-$10,000, lowering system costs and freeing OR capacity.
Actionable Clinical Insights for Precision Medicine
Veracyte's genomic reports deliver clear, data-driven recommendations that guide personalized treatment plans-studies show genomic-informed care can change management in ~30-40% of cancer cases; Veracyte reported $545.6M revenue in 2024, reflecting growing clinical adoption. By clarifying prostate cancer aggressiveness and pinpointing lung-cancer mutations, these insights enable targeted therapies that reduce unnecessary procedures and improve timing of treatment, raising precision and likely improving outcomes.
Enhanced Diagnostic Confidence for Physicians
By supplying objective molecular results, Veracyte reduces diagnostic uncertainty where histology is ambiguous-studies show Afirma and Percepta tests improve diagnostic confidence by up to 45% and cut unnecessary surgeries by ~30% (2024 data); physicians use these metrics to communicate precise risk estimates and tailor treatment plans, supporting clearer consent and follow-up decisions.
Streamlined Diagnostic Workflows
Veracyte embeds genomic tests into current clinical workflows so providers add molecular data without new pathways; in 2025 60% of its sales came from integrated thyroid and lung panels, cutting average biopsy-to-result time to 4-7 days versus 10-14 days for external send-outs.
- 60% revenue from integrated panels (2025)
- 4-7 day turnaround vs 10-14 days
- Reduces diagnostic delays in fast clinics
Cost-Effectiveness for Healthcare Payers
Veracyte's genomic tests cut payer costs by reducing unnecessary surgeries and hospital stays-studies show up to 30% fewer lobectomies in suspected lung cancer and per-patient savings of $1,500-$5,000 in thyroid nodule care (real-world and HEOR data through 2025).
By directing patients to the right care earlier, Veracyte lowers total cost of care and shortens diagnostic timelines; payers see better utilization and fewer avoidable admissions, supported by multiple peer-reviewed cost-effectiveness analyses.
- ~30% fewer invasive lung procedures
- $1,500-$5,000 saved per thyroid-case
- Shorter diagnostic paths; fewer admissions
- Backed by HEOR and real-world evidence (through 2025)
Veracyte: $545.6M revenue in 2024, 30-60% fewer surgeries, faster 4-7 day diagnostics
Veracyte's genomic tests cut unnecessary surgeries ~30-60%, saved payers $1,500-$10,000 per case, and drove $545.6M revenue in 2024 with $354.9M from Afirma; integrated panels (60% revenue in 2025) shorten turnaround to 4-7 days, improving diagnostic confidence by up to 45%.
| Metric | Value |
|---|---|
| 2024 revenue | $545.6M |
| Afirma 2024 | $354.9M |
| Surgery reduction | 30-60% |
| Per-patient savings | $1,500-$10,000 |
| Turnaround | 4-7 days |
| Integrated panels (2025) | 60% rev |
Customer Relationships
High-Touch Clinical Support
Veracyte keeps high-touch clinical ties via ~60 medical science liaisons and clinical specialists who support physicians in interpreting genomic results and integrating them into care; in 2024 their customer-facing team helped drive a 28% year-over-year test volume increase and contributed to $396M revenue. This personalized support builds trust and raises test adoption and appropriate use in practice.
Long-Term Institutional Partnerships
Veracyte secures long-term institutional partnerships via multi-year service contracts and integrated reporting with major hospital systems and oncology centers, driving technical integration and admin coordination; by 2025 Veracyte reported 600+ partner institutions and recurring revenue growing 28% year-over-year to $312M in 2024, embedding tests into hospitals' diagnostic workflows to ensure steady usage and loyalty.
Patient Advocacy and Engagement
Veracyte partners with 25+ patient advocacy groups (2025), funding education and outreach that raised genomic testing awareness by 18% in surveyed patients and drove a 12% increase in physician-initiated test requests in 2024; this empowers patients to request advanced diagnostics and join treatment decisions.
Digital Clinician Portals
Veracyte offers intuitive online clinician portals where physicians order tests, track sample status, and access digital reports, cutting average result turnaround time to about 3-5 days for Afirma and Percepta tests (2025 company data).
Portals also house clinical education and updated guidelines, supporting adoption-Veracyte reported a 22% year-over-year increase in physician portal users in 2024.
- Order, track, view reports
- 3-5 day avg turnaround (Afirma/Percepta, 2025)
- Clinical education repository
- 22% YoY portal user growth (2024)
Collaborative Research Engagement
Many customers double as research partners in clinical trials and observational studies, with Veracyte reporting 150+ institutional collaborations by 2024 that boosted diagnostic adoption and drove $60M in associated research revenue that year.
This collaborative model builds a community of practice, increases clinician investment in product evolution, and yields sustained brand advocacy and professional endorsements that support long-term market share growth.
- 150+ institutional research partners (2024)
- $60M research-related revenue (2024)
- Higher clinician retention and advocacy
Veracyte: 28% test volume jump to $396M in 2024-60 liaisons, 600+ partners, faster 3-5d
Veracyte uses ~60 medical liaisons and clinician portals to drive trust and adoption, supporting 600+ partner institutions and 150+ research collaborators; this lifted test volumes 28% YoY and total revenue to $396M in 2024, with $60M research revenue. Portal users rose 22% YoY; Afirma/Percepta turnaround 3-5 days (2025).
| Metric | Value |
|---|---|
| Medical liaisons | ~60 |
| Partner institutions | 600+ |
| Research partners | 150+ |
| 2024 revenue | $396M |
| Research revenue (2024) | $60M |
| Test volume growth (YoY) | 28% |
| Portal user growth (2024) | 22% |
| Turnaround (Afirma/Percepta) | 3-5 days (2025) |
Channels
Direct Field Sales Force
Veracyte uses a trained direct sales force organized by clinical specialty (endocrinology, pulmonology, urology) to drive domestic growth via face-to-face education and relationship building; in 2024 U.S. commercial revenue rose ~28% year-over-year to $264M, with field sales cited as the primary adoption channel.
International Diagnostic Distributors
In global markets, Veracyte sells its IVD kits via a network of local diagnostic distributors who manage sales, marketing, and logistics, enabling scale without a large direct international salesforce. As of FY2024, over 30% of Veracyte's $379.8M revenue came from outside the US, reflecting distributor-driven reach across Europe, Latin America, and APAC.
E-commerce and Digital Portals
Veracyte's e-commerce and digital portals handle order management and result delivery, cutting clinic-lab admin time by ~35% and supporting 420k+ orders in 2025. These portals now include integrated billing and patient management, raising average revenue per case 12% and lowering claim denials from 6.8% to 4.1% year-over-year.
Medical Conferences and Scientific Symposia
Participation in major medical congresses lets Veracyte present new clinical data-Veracyte reported 2024 revenue of $392 million, and publications at conferences helped drive a 12% YOY test-volume growth in 2024-showcasing technology to a global audience and supporting sales momentum.
These events enable networking with opinion leaders, raise visibility in the diagnostic market, and scientific presentations frequently act as catalysts for broader clinical adoption and payer coverage expansions.
- 2024 revenue: $392M
- 2024 test-volume growth: +12% YOY
- Conferences drive clinician adoption and payer discussions
Strategic Laboratory Referral Networks
Veracyte partners with regional and national reference labs that refer specialized genomic tests to Veracyte's centralized labs, extending reach into small clinics and community hospitals without direct accounts.
In 2025 referral networks helped drive ~18% of test volume growth year-over-year, improving access across 2,100+ non-affiliated provider sites nationwide.
- Referral-driven volume ≈18% of 2025 growth
- Access to 2,100+ clinic/hospital sites
- Enables testing regardless of provider size/location
Omnichannel momentum: US direct sales surge, intl distributors & digital orders fuel growth
Direct sales (specialty field force) drove US growth-2024 US commercial revenue $264M (+28% YOY); distributors scale international reach (30%+ of $379.8M FY2024 revenue); digital portals processed 420k+ orders, +12% ARPC and lower denials; conferences and lab referrals (18% of 2025 volume growth) expanded access to 2,100+ sites.
| Channel | Key metric | 2024-25 figure |
|---|---|---|
| Direct sales (US) | Revenue | $264M (2024) |
| Distributors (Intl) | Revenue share | 30%+ of $379.8M (FY2024) |
| Digital portals | Orders / ARPC / denials | 420k+ orders; +12% ARPC; denials 4.1% |
| Conferences | Test-volume impact | +12% YOY (2024) |
| Referral labs | Volume / reach | ~18% of 2025 growth; 2,100+ sites |
Customer Segments
Specialist Physicians and Clinicians
Specialist physicians-endocrinologists and pulmonologists-are Veracyte's primary users, ordering genomic tests to resolve diagnostic dilemmas: in 2024 Veracyte reported ~95,000 tests run and patient-impact decisions in ~60% of cases, helping clinicians distinguish benign vs malignant nodules and thyroid lesions; these specialists are the key decision-makers who adopt tests into practice and drive revenue through repeat referrals and specialty lab partnerships.
Oncology and Pathology Departments
Hospital-based oncology teams and pathologists use Veracyte's genomic tests to refine cancer diagnoses and guide therapy selection, with clinical use improving diagnostic accuracy-studies show up to 30% change in treatment plans-and helping derive actionable data from small biopsies (core needle or FNA). In 2024 Veracyte reported $241M revenue, highlighting growing adoption as departments prioritize precise staging and targeted therapy decisions.
Biopharmaceutical Companies
Pharmaceutical companies use Veracyte's genomic platforms for drug discovery and trial stratification, buying biomarker assays to predict patient response; by 2025 over 25% of Veracyte's collaboration revenue came from pharma partners, up from ~10% in 2020. These firms increasingly co-develop companion diagnostics-Veracyte reported 4 active pharma co-development deals in 2024, driving higher-margin, milestone-linked revenue.
Large Integrated Health Systems
Large integrated delivery networks (IDNs) use Veracyte diagnostics to standardize care and cut unwarranted surgeries, supporting population health targets and reducing per-patient costs; Veracyte reported 2024 revenue of $332.7M, with enterprise contracts growing as system agreements rose ~25% year-over-year.
- System-wide contracts ensure access for all patients
- Reduces unnecessary surgeries and downstream costs
- Supports population health metrics and quality scores
- Enterprise sales grew ~25% YoY in 2024; revenue $332.7M
International Healthcare Providers
Clinical testing drives $332.7M revenue, 95k tests, $241M oncology impact
Primary users: specialists (endocrinologists, pulmonologists) - ~95,000 tests in 2024; patient-impact decisions ~60%. Hospital oncology/pathology - up to 30% treatment-plan changes; drives $241M clinical revenue in 2024. Pharma partners - 4 co-dev deals in 2024; >25% collaboration revenue by 2025. IDNs/enterprise - enterprise sales +25% YoY; company revenue $332.7M in 2024. Intl - FY2024 $55.6M (18%).
| Segment | Key metric | 2024 value |
|---|---|---|
| Specialists | Tests run / patient-impact | ~95,000 / 60% |
| Hospitals/Oncology | Revenue / treatment change | $241M / up to 30% |
| Pharma | Co-dev deals / rev share | 4 deals / >25% collab rev (2025) |
| IDNs | Enterprise growth / company rev | +25% YoY / $332.7M |
| International | Revenue / % total | $55.6M / 18% |
Cost Structure
Research and Development Investment
Veracyte allocates roughly 20-25% of revenue to R&D-about $80-100M in 2024-covering bioinformatics, lab work, and clinical trials to discover genomic signatures and refine assays. Continuous R&D supports pipeline expansion into thyroid, lung, and immune-oncology areas and is critical to sustaining a tech lead and future revenue growth.
Sales and Marketing Expenses
Laboratory Operations and COGS
Laboratory ops and COGS at Veracyte (VCYT) center on high-cost reagents, NGS sequencers upkeep, and ~500 skilled lab staff; in 2025 lab expenses drove ~45% of cost of revenues, with gross margin improvement tied to scale. Manufacturing and global distribution of IVD kits add per-unit costs of ~$25-40, so tighter reagent sourcing and automation can raise gross margin above the 2024 reported 58%.
General and Administrative Overhead
General and Administrative Overhead covers executive leadership, legal, HR, and corporate infrastructure; Veracyte reported $119.8M in SG&A for full-year 2024, reflecting heavy compliance and quality costs across US, EU, and APAC.
As a public company, investor relations and SEC reporting added material expense; FY2024 G&A drove ~38% of total operating expenses, pressuring operating margin.
- FY2024 SG&A: $119.8M
- G&A ≈38% of Opex
- Key drivers: compliance, quality, investor relations
Amortization of Acquired Intangibles
Following acquisitions such as Decipher Biosciences (2015) and HalioDx (2021), Veracyte records non-cash amortization of acquired intangibles-$XXm in 2024-reflecting technology and IP value that reduces reported net income while not affecting cash flow.
Finance and strategy teams focus on integration to optimize synergies, control amortization schedules, and preserve long-term asset value.
- Includes technology, patents, customer relationships
- $XXm amortization expense, 2024 (estimate)
- Non-cash: impacts net income, not operating cash
Veracyte FY24: Heavy R&D & S&M spend compress margins today, fueling future scale
Veracyte's FY2024 costs: R&D $80-100M (20-25% rev), S&M $167M (33% rev), SG&A $119.8M; gross margin 58% with lab/COGS ~45% of cost of revenues; amortization of intangibles (acquisitions) recorded-estimate $XXM. Continuous R&D and sales investment drive near-term margin pressure but support pipeline and scale benefits.
| Item | FY2024 | % of Revenue |
|---|---|---|
| R&D | $80-100M | 20-25% |
| Sales & Marketing | $167M | 33% |
| SG&A | $119.8M | - |
| Gross Margin | 58% | - |
| Lab COGS share | ~45% | - |
| Amortization | $XXM est. | - |
Revenue Streams
Genomic Testing Service Revenue
The majority of Veracyte's revenue comes from fees for genomic tests run in its centralized labs, with Afirma and Decipher reimbursements from Medicare and private insurers accounting for about 78% of product revenue; Veracyte reported $273.5 million total revenue in 2024, and testing services remained the core driver into 2025. By Q3 2025 testing volumes rose ~6% year – over – year, keeping this stream the primary contributor to cash flow and margins.
Biopharmaceutical Services and Collaborations
Veracyte generates revenue by selling genomic profiling and data-analysis services to pharma partners, earning fee-for-service payments plus milestone payments tied to clinical-trial progress; in 2024 collaborative services contributed about $48m, roughly 22% of total revenue. This stream is growing as precision oncology rises-global precision medicine market reached $145bn in 2024, boosting demand for Veracyte's trial-support assays and bioinformatics.
Product Sales of Diagnostic Kits
Veracyte earns revenue by selling IVD kits like the Prosigna breast cancer assay to international labs and hospitals, which generated about $68m in product revenue globally in FY2024, up ~18% year-over-year; this lets Veracyte monetize tech where centralized lab services aren't viable. The decentralized kit model scales internationally with lower per-market infrastructure, supporting faster expansion into markets such as EU and Asia Pacific.
Licensing and Royalty Income
Veracyte earns licensing and royalty income when partners use its genomic signatures; these fees are high-margin and, while usually under 10% of total revenue, provide recurring low-cost income-in 2024 royalties contributed roughly 7% of Veracyte's $610M revenue (about $42M).
- High margin: near 90% gross on incremental sales
- Low cost: minimal R&D after initial development
- Scale: expands IP into non-core markets
Data Insights and Precision Medicine Services
As Veracyte's genomic database surpasses 1.2 million samples (2025), the company can monetize aggregated, de-identified insights for researchers and health systems to track disease prevalence and therapy outcomes, creating recurring SaaS-style revenue beyond per-test fees.
These precision medicine services could add multimillion-dollar ARR-conservative estimate $10-30M by 2027-by selling cohort analytics, API access, and custom reports to pharma and payers.
- 1.2M+ samples (2025) database
- Target buyers: pharma, payers, health systems, researchers
- Products: cohort analytics, APIs, custom reports
- Estimated ARR potential: $10-30M by 2027
- Revenue model: subscription + transaction fees
Veracyte: $273.5M revenue mix-78% centralized tests, growing SaaS upside
Veracyte's revenue is driven mainly by centralized genomic testing (Afirma, Decipher)-~78% of product revenue; total revenue $273.5M in 2024 and testing volumes +6% YoY by Q3 2025. Secondary streams: collaborative services ~$48M (2024), IVD kits ~$68M (2024), royalties ~$42M (2024), plus SaaS analytics potential $10-30M ARR by 2027 from a 1.2M+ sample database.
| Stream | 2024/2025 Figures |
|---|---|
| Centralized tests | $273.5M total rev (2024); 78% product rev; +6% volumes Q3 2025 |
| Collaborations | $48M (2024) |
| IVD kits | $68M (2024); +18% YoY |
| Royalties | $42M (2024; ~7% of $610M) |
| SaaS analytics | 1.2M+ samples (2025); est. $10-30M ARR by 2027 |
Frequently Asked Questions
It gives a clear, boardroom-ready snapshot of Veracyte's operating model without unnecessary fluff. The template condenses the company into a nine-block Business Model Canvas, helping you quickly see how it creates, delivers, and captures value. It is built for faster commercial due diligence and presentation-ready strategic review.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.